

MONOOXYGENASE AND GLUCURONYLTRANSFERASE ACTIVITIES IN SHORT TERM CULTURES OF ISOLATED RAT HEPATOCYTES

L. R. SCHWARZ, R. GÖTZ, Th. WOLFF and F. J. WIEBEL

Dept. Toxicology, Gesellschaft f. Strahlen- u. Umweltforschung, D-8042 Neuherberg/München, FRG

Received 4 December 1978

1. Introduction

Isolated hepatocytes in culture are useful for the study of many parameters of drug metabolism and action which can not be examined *in vivo*. However, the applicability of the culture system may be severely limited by changes in the level of drug-metabolizing enzymes during culture. A number of studies have shown that cytochrome *P*-450-containing monooxygenases which play a crucial role in the activation of xenobiotics to their cytotoxic, mutagenic or carcinogenic form [1,2] were reduced by $\geq 66\%$ after 24 h in culture [3–5]. Little is known about the potential loss of monooxygenase activities during the early hours of hepatocyte culture [6] and the specificity of their decline.

Another important factor in the overall metabolism of xenobiotics is the activity of conjugating enzymes. A differential loss or increase in microsomal monooxygenase and conjugase activities might readily alter the steady state level of the reactive intermediates and change the metabolite pattern. Thus we examined the stability of two glucuronyl-transferase activities during short term hepatocyte cultures.

In this study we observed that the *in vitro* activities of two monooxygenases, aldrin epoxidation and benzo[a]pyrene hydroxylation*, and the glucuronidation of morphine decreased by 50–60% in hepatocytes from adult rats cultured for 10 h. In contrast, the glucuronidation of naphthol declined by $\geq 25\%$ during this period. The data indicate that the

absolute and relative activities of drug-metabolizing enzymes change rapidly during early adaptation of hepatocytes to culture conditions, and underline the need to use caution in extrapolating observations in hepatocytes cultured for more than a few hours to hepatic drug metabolism *in vivo*.

2. Materials and methods

2.1. Isolation and viability of hepatocytes

Hepatocytes were isolated from male Sprague Dawley rats (~200 g body wt) following established procedures [7,8] except that hyaluronidase was omitted from the perfusion medium. Some animals were pretreated by intraperitoneal injection of 16 mg 5,6-benzoflavone in 1.5 ml corn oil 24 h before isolation of hepatocytes. As described previously, cell preparations were considered satisfactory for experimental use when:

- (i) Trypan-blue exclusion was $>92\%$;
- (ii) The respiratory control quotient was >2.0 after addition of carbonylcyanide-*m*-chlorophenylhydrazone ($2 \mu\text{M}$);
- (iii) Stimulation of oxygen consumption was $\geq 20\%$ after 1 mM succinate [7,8].

After 10 h incubation ~90% of the hepatocytes formed aggregates of more than 50 cells. Trypan-blue was taken up almost exclusively by single cells.

2.2. Incubation of hepatocytes

Freshly-isolated hepatocytes (1.2×10^6 cells/ml, equiv. 2.4 mg protein) were incubated in spinner

* This monooxygenase function is also known as aryl hydrocarbon hydroxylase (cf. [2])

flasks under a 95% O₂, 5% CO₂ atmosphere in 100 ml Waymouth MB 752/1 medium containing 2 mM glutamine, 5 mM L-lactate, 100 µg/ml streptomycin, and 100 units/ml penicillin [9].

2.3. Enzyme assays

Aliquots of 1–3 ml were removed from the incubation mixture and frozen at –70°C to be used for enzyme assays within 3 weeks. Aldrin epoxidation was determined by gas chromatography according to [10] with minor modifications [11]; benzo[a]pyrene hydroxylation was determined by spectrofluorimetry as in [12]. Glucuronidation was naphthol and morphine was assayed according to [13] and [14] respectively, with the addition of 0.1% Brij 58 (Atlas Chemie, Essen) to activate the glucuronyltransferases [15]. Protein was determined by a modified biuret method [16].

3. Results and discussion

As shown in fig.1,2, the two monooxygenase activities, aldrin epoxidation and benzo[a]pyrene-hydroxylation, declined by ~60% during the first 10 h of hepatocyte culture. The decrease of enzyme activities was similar in hepatocytes from untreated rats in which cytochrome P-450-dependent monooxygenases predominate [17], or rats pretreated with 5,6-benzoflavone* (5,6-BF) which strongly induces a different, cytochrome P-448-dependent benzo[a]pyrene monooxygenase [18] (fig.1,2B). The rates of decline are compatible with the low activities of aminopyrene-N-demethylation, or aniline- and benzo[a]pyrene monooxygenase in 24 h old hepatocyte cultures observed [3]. It is interesting to note that polycyclic hydrocarbon-induced benzo[a]pyrene hydroxylation in hamster embryo cells decreased at a comparable rate when protein synthesis was inhibited or when the inducer was removed from the medium [2].

In order to examine whether the two forms of benzo[a]pyrene monooxygenases lose their activities at different rates during hepatocyte culture we studied the effects of the modifier 7,8-benzoflavone. This

* 5,6-Benzoflavone belongs to the class of polycyclic hydrocarbon inducers typified by 3-methylcholanthrene [18]




Fig.1. In vitro activity of aldrin epoxidation of cultured hepatocytes. Hepatocytes were isolated from untreated rats or rats treated with 5,6-benzoflavone. Aldrin was 0.1 mM, and protein 0.5 mg/ml. Values represent the % of initial enzyme activities immediately after isolation of the hepatocytes. The initial activities were 0.35–1.0 (untreated) and 0.09 (5,6-BF-treated) nmol dieldrin · min⁻¹ · mg protein⁻¹. The data show a typical experiment of 3 (untreated) and 2 (5,6-BF-treated) determinations. Duplicates varied by >10% of the mean.

compound strongly inhibits the monooxygenase induced by polycyclic hydrocarbon-type inducers but does not affect or stimulate the constitutive monooxygenase in hepatic microsomes [19]. As shown in fig.2A,2B, the specific response of benzo[a]pyrene monooxygenase to 7,8-benzoflavone observed in hepatic microsomes was retained in cultured hepatocytes. Furthermore, the degree of stimulation or inhibition of benzo[a]pyrene hydroxylation by the modifier did not appreciably change over the 10 h period of hepatocyte culture suggesting that the ratio of the two monooxygenase forms remains unaltered under these conditions.

These results are in agreement with the parallel




Fig.2. In vitro benzo[a]pyrene monooxygenase activity of cultured hepatocytes. Hepatocytes were isolated from (A) untreated rats or (B) rats treated with 5,6-benzoflavone. In vitro 7,8-benzoflavone was added together with the substrate in 50 μ l acetone to give 50 μ M final conc. Values represent the % of initial enzyme activities which were determined immediately after isolation of the hepatocytes. Initial specific activities in cell preparations (A) and (B) were 15 and 70 $\text{pmol} \cdot \text{min}^{-1} \cdot \text{mg protein}^{-1}$, respectively. (A) and (B) show typical results of 3 and 2 experiments, respectively. Triplicate determinations varied by $>10\%$ of the mean.

decline in the activities of induced and constitutive benzo[a]pyrene monooxygenase. It should be noted that aldrin epoxidation which showed a similar loss of activity represents a cytochrome *P*-450-dependent form different from that oxidizing benzo[a]pyrene (Th.W., unpublished results). In conclusion, our data give no indication of a selective decrease in any of the monooxygenases tested in our hepatocyte cultures.

This is different for the two forms of glucuronyltransferases studied (fig.3). The glucuronidation of morphine declined at the same rate as the monooxygenase activities, i.e., $\sim 55\%$ during the 10 h culture period. However, the glucuronidation of naphthol appeared to be much more stable and was reduced by $>25\%$ over this time period. Thus, a different lability response to the culture conditions might afford another distinction of the two forms of glucuronyl transferases which are already characterized by their physico-chemical properties, their substrate and inducer specificities [20]. Alterations of culture conditions suggested by others, such as addition of




Fig.3. In vitro activity of morphine and naphthol glucuronidation of cultured hepatocytes. Morphine and naphthol were used at 1.3 mM and 0.45 mM final conc. Values represent the % of initial enzyme activities immediately after isolation of the hepatocytes. Initial specific activities of the glucuronidation of morphine and naphthol were 1.4 and 9 $\text{nmol} \cdot \text{min}^{-1} \cdot \text{mg protein}^{-1}$, respectively. The data show typical results of 4 experiments which varied by $>10\%$.

serum [6,9] or of a mixture of various hormones [5,21], did not significantly affect the decline in glucuronyltransferase and monooxygenase activities (data not shown).

The present data show that the activity of microsomal enzymes involved in the activation and inactivation of xenobiotics differentially decrease during the first 10 h of hepatocyte culture suggesting that drug metabolism in these early hepatocyte cultures may not truly reflect hepatic metabolism in vivo.

Acknowledgements

We wish to thank Ms U. Hamm, Mr P. Bannach, and Ms H. Wanders for their skillful technical assistance, and Ms Judy Byers for her assistance in preparing the manuscript. We gratefully acknowledge the continuous support and critical advice of Prof. Dr Greim.

References

- [1] Miller, J. (1970) *Cancer Res.* 30, 559–576.
- [2] Gelboin, H. V. and Wiebel, F. J. (1971) *Ann. NY Acad. Sci.* 179, 529–547.
- [3] Guzelian, P. S., Bissell, D. M. and Meyer, U. A. (1977) *Gastroenterology* 72, 1232–1239.
- [4] Michalopoulos, G., Sattler, G. L. and Pitot, H. C. (1976) *Life Sci.* 18, 1139–1144.
- [5] Decad, G. M., Hsieh, D. P. H. and Byard, J. L. (1977) *Biochem. Biophys. Res. Commun.* 78, 279–287.
- [6] Erickson, R. R. and Holtzman, J. L. (1976) *Biochem. Pharmacol.* 25, 1501–1506.
- [7] Baur, H., Kasperek, S. and Pfaff, E. (1975) *Hoppe-Seyler's Z. Physiol. Chem.* 356, 827–838.
- [8] Schwarz, L. R., Schwenk, M., Pfaff, E. and Greim, H. (1977) *Biochem. Pharmacol.* 26, 2433–2437.
- [9] Jeejeebhoy, K. N., Ho, J., Greenberg, G. R., Phillips, M. J., Bruce-Robertson, A. and Sodtke, U. (1975) *Biochem. J.* 146, 141–155.
- [10] Krieger, R. I., Gee, S. J., Miller, J. L. and Thongsinthusak, T. (1976) *Drug Metab. Dispos.* 4, 28–34.
- [11] Wolff, T. (1977) *Naunyn-Schmiedeberg's Arch. Pharmacol.* 297, suppl. II, 7.
- [12] Wiebel, F. J., Brown, S., Waters, H. L. and Selkirk, J. K. (1977) *Arch. Toxicol.* 39, 133–148.
- [13] Bock, K. W. and White, I. N. H. (1974) *Eur. J. Biochem.* 46, 451–459.
- [14] Yeh, S. Y. and Woods, L. A. (1970) *J. Pharm. Sci.* 59, 380–383.
- [15] Bock, K. W., Huber, E. and Schlote, W. (1977) *Naunyn-Schmiedeberg's Arch. Pharmacol.* 296, 199–203.
- [16] Szarkowska, L. and Klingenberg, M. (1963) *Biochem. Z.* 338, 674–697.
- [17] Guengerich, F. P. (1977) *J. Biol. Chem.* 252, 3970–3979.
- [18] Boobis, A. R., Nebert, D. W. and Felton, J. S. (1977) *Mol. Pharmacol.* 13, 259–268.
- [19] Wiebel, F. J. and Gelboin, H. V. (1975) *Biochem. Pharmacol.* 24, 1511–1515.
- [20] Bock, K. W., von Clausbruch, U. C., Josting, D. and Ottenwälder, H. (1977) *Biochem. Pharmacol.* 26, 1097–1100.
- [21] Paine, A. J. and Legg, R. F. (1978) *Biochem. Biophys. Res. Commun.* 81, 672–679.